ClinicalTrials.gg
CompletedNCT02892149Updated Jun 28, 2022Results posted

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Completed at 278 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-28.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,554
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
Largest of 27
3,554 · median 60
Started
2016
with 4 others
Phase 3
14 of 27
none open now
Registered
11th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one has the largest enrollment, is one of 5 that started in 2016, is one of 14 in phase 3, and was the 11th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

A multicenter, randomized, open-label, active-controlled Phase 3 study for the maintenance treatment of anemia in participants with dialysis-dependent chronic kidney disease (DD-CKD)

Read the detailed description

This is a multicenter, randomized, open-label, active-controlled Phase 3 study of the efficacy and safety of Vadadustat versus Darbepoetin alfa for the maintenance treatment of anemia in participants with DD-CKD

03

Conditions studied

  • Anemia
  • Dialysis-Dependent Chronic Kidney Disease

Keywords

  • AKB-6548
  • Chronic kidney disease
  • anemia
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • erythropoietin
  • kidney
  • renal
  • oral anemia treatment
  • hemoglobin
  • hypoxia-inducible factor
  • HIF
  • hypoxia-inducible factor prolyl-hydroxylase inhibitor
  • HIF-PHI
  • efficacy
  • safety
  • Phase 3
  • cardiovascular
  • DD-CKD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Receiving chronic maintenance dialysis (either peritoneal or hemodialysis) for end-stage kidney disease for at least 12 weeks prior to Screening
  • Currently maintained on erythropoiesis-stimulating agent therapy, with a dose received within 6 weeks prior to or during Screening
  • Mean Screening between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the US and between 9.0 and 12.0 g/dL (inclusive) outside of the US
  • Serum ferritin ≥100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥20% during Screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease or participants with active bleeding or recent blood loss
  • Uncontrolled hypertension
  • Red blood cell transfusion within 8 weeks prior to randomization
  • Anticipated to recover adequate kidney function to no longer require dialysis
  • Severe heart failure at Screening ( Class IV)
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure, or stroke within 12 weeks prior to or during Screening
  • to Vadadustat, Darbepoetin alfa, or any of their
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,554 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Drug: Vadadustat

  • Active comparator
    Darbepoetin alfa

    Drug: Darbepoetin alfa

Interventions

  • Oral dose administered once daily for ≥36 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.

    Also known as: AKB-6548

  • Subcutaneous or intravenous dose administered for ≥36 weeks. Initial dose based on the current package insert for investigational sites in the United States (US), and the Summary of Product Characteristics for all other investigational sites (non-US) for adult participants with chronic kidney disease not on dialysis. For participants already on Darbepoetin alfa, the initial dosing regimen in the study was based on the prior dosing regimen.

    Also known as: Aranesp

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 24 to 36

  2. Median Time to First Major Adverse Cardiovascular Event (MACE)

    MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 170 weeks

Secondary outcomes

  1. Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

    The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

    Time frame: Baseline; Weeks 40 to 52

  2. Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 170 weeks

  3. Median Time to First Cardiovascular MACE

    MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 170 weeks

  4. Median Time to First Cardiovascular Death

    Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 170 weeks

  5. Median Time to First All-cause Mortality

    Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

    Time frame: Up to 170 weeks

Other outcomes

  1. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  2. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)

    Time frame: Weeks 24 to 36

  3. Exploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  4. Exploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)

    Time frame: Weeks 40 to 52

  5. Exploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  6. Exploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit

    Time frame: Baseline; up to Week 52

  7. Exploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure

    Time frame: Baseline; Weeks 24 to 36

  8. Exploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron

    Time frame: Up to Week 52

  9. Exploratory - Proportion of Participants Receiving IV Iron Therapy

    Time frame: Up to Week 52

  10. Exploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)

    Time frame: Up to Week 52

07

Results

Posted Jun 28, 2022

Participant flow

Participant flow — Overall Study
MilestoneVadadustatDarbepoetin Alfa
Started17771777
Completed14251421
Not completed352356
Withdrew: Death262278
Withdrew: Withdrawal by subject5347
Withdrew: Lost to follow-up3731

Outcome measures

PrimaryChange From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Primary Efficacy Period was calculated as the average Hb value over Weeks 24 to 36. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (United States \[US\] versus European Union \[EU\] versus Rest of World \[ROW\]), and New York Heart Association congestive heart failure (NYHA CHF) class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 24 to 36
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)
Grams per deciliter (g/dL)VadadustatDarbepoetin Alfa
Change From Baseline in Hemoglobin (Hb) to the Average Over the Primary Efficacy Period (Weeks 24 to 36)0.19 ± 0.0320.36 ± 0.032
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.17 · 95% CI -0.23 to -0.10
PrimaryMedian Time to First Major Adverse Cardiovascular Event (MACE)

MACE was defined as all-cause mortality, non-fatal myocardial infarction (MI), or non-fatal stroke. The primary safety outcome was positively adjudicated first MACE, which was defined as any death, Endpoint Adjudication Committee (EAC)-confirmed non-fatal MI, or EAC-confirmed non-fatal stroke occurring between the first dose date and each participant's last participation date. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 170 weeks
Reported as:
Median · Weeks
Median Time to First Major Adverse Cardiovascular Event (MACE)
WeeksVadadustatDarbepoetin Alfa
Median Time to First Major Adverse Cardiovascular Event (MACE)48.86 (26.43 to 79.71)48.00 (22.43 to 75.57)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = 0.4745 · Hazard ratio (hr): 0.96 · 95% CI 0.828 to 1.117Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4877 · Hazard ratio (hr): 0.96 · 95% CI 0.833 to 1.113Based on non-parametric analysis.
SecondaryChange From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)

The Baseline average was calculated as the average of the Hb values obtained at the screening visit closest to the date of randomization and the randomization visit. The average for the Secondary Efficacy Period was calculated as the average Hb value over Weeks 40 to 52. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with Baseline hemoglobin concentration (\<10.0 versus ≥10.0 g/dL), geographic region (US versus EU versus ROW), and NYHA CHF class (Class 0 \[no CHF\] or I versus II or III) as covariates.

Time frame:
Baseline; Weeks 40 to 52
Reported as:
Least squares mean · g/dL
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)
g/dLVadadustatDarbepoetin Alfa
Change From Baseline in Hb to the Average Over the Secondary Efficacy Period (Weeks 40 to 52)0.23 ± 0.0350.41 ± 0.033
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Least squares mean difference: -0.18 · 95% CI -0.25 to -0.12
SecondaryMedian Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Hospitalization for EAC adjudicated heart failure included presentation of participants to an acute care facility requiring an overnight hospitalization (change in calendar day) with an exacerbation of heart failure requiring treatment. EAC confirmed thromboembolic events for this secondary outcome measure included arterial thrombosis, deep vein thrombosis, and pulmonary embolism. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 170 weeks
Reported as:
Median · Weeks
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis
WeeksVadadustatDarbepoetin Alfa
Median Time to First MACE Plus Hospitalization for Heart Failure or Thromboembolic Event Excluding Vascular Access Thrombosis43.29 (21.86 to 73.14)45.21 (22.29 to 73.86)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = 0.3718 · Hazard ratio (hr): 0.96 · 95% CI 0.832 to 1.097Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4096 · Hazard ratio (hr): 0.96 · 95% CI 0.840 to 1.096Based on non-parametric analysis.
SecondaryMedian Time to First Cardiovascular MACE

MACE was defined as all-cause mortality, non-fatal MI, or non-fatal stroke. Cardiovascular MACE analysis differed from the primary MACE endpoint as it included only deaths adjudicated by the EAC as cardiovascular deaths (i.e, only EAC-confirmed cardiovascular deaths) in addition to first events of non-fatal MI or non-fatal stroke. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 170 weeks
Reported as:
Median · Weeks
Median Time to First Cardiovascular MACE
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular MACE44.57 (23.29 to 81.86)43.57 (20.71 to 73.93)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = 0.3875 · Hazard ratio (hr): 0.94 · 95% CI 0.777 to 1.131Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.5007 · Hazard ratio (hr): 0.95 · 95% CI 0.795 to 1.144
SecondaryMedian Time to First Cardiovascular Death

Cardiovascular death included EAC adjudicated fatal MI, pump failure, sudden death, presumed sudden death, fatal stroke, fatal pulmonary embolism, cardiovascular procedure-related death, other cardiovascular death, and presumed cardiovascular death. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 170 weeks
Reported as:
Median · Weeks
Median Time to First Cardiovascular Death
WeeksVadadustatDarbepoetin Alfa
Median Time to First Cardiovascular Death46.14 (29.43 to 79.00)47.64 (24.57 to 74.14)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = 0.6281 · Hazard ratio (hr): 0.96 · 95% CI 0.761 to 1.203Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Gray's test · p = =0.6284 · Hazard ratio (hr): 0.96 · 95% CI 0.766 to 1.195Based on non-parametric analysis.
SecondaryMedian Time to First All-cause Mortality

Only events that were positively adjudicated and confirmed by the EAC were included in the MACE analyses. INNOVATE MACE results and analysis, by design, was performed on pooled data from studies AKB-6548-CI-0016 (NCT02865850) and AKB-6548-CI-0017 (NCT02892149). Results and statistical analysis from study AKB-6548-CI-0017 has been reported in below table and under section "Statistical Analysis 1". Results and statistical analysis of the pooled data from studies AKB-6548-CI-0016 and AKB-6548-CI-0017 has been reported under section "Statistical Analysis 2" of this outcome measure.

Time frame:
Up to 170 weeks
Reported as:
Median · Weeks
Median Time to First All-cause Mortality
WeeksVadadustatDarbepoetin Alfa
Median Time to First All-cause Mortality50.79 (30.29 to 80.50)50.43 (26.14 to 78.86)
Statistical analysis
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = 0.5811 · Hazard ratio (hr): 0.96 · 95% CI 0.816 to 1.136Based on non-parametric analysis.
  • Vadadustat vs Darbepoetin Alfa · Log Rank · p = =0.4878 · Hazard ratio (hr): 0.95 · 95% CI 0.812 to 1.118Based on non-parametric analysis.
Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Primary Evaluation Period (Weeks 24 to 36)
Time frame:
Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Time With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With Hb Values Within the Target Range During the Secondary Evaluation Period (Weeks 40 to 52)
Time frame:
Weeks 40 to 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants With an Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Time to Achieve Hb Increase of >1.0 g/dL From Baseline Visit
Time frame:
Baseline; up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Change in Hb Between Baseline (Mean Pretreatment Hb) and the Primary Evaluation Period (Mean Hb From Weeks 24 to 36) Stratified by Pre-baseline Erythropoiesis-stimulating Agent (ESA) Exposure
Time frame:
Baseline; Weeks 24 to 36

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Mean Monthly Dose of Intravenous (IV) Elemental Iron Administered in Participants Who Have Received IV Iron
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving IV Iron Therapy
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Other pre-specifiedExploratory - Proportion of Participants Receiving Red Blood Cells (RBCs) Transfusion(s)
Time frame:
Up to Week 52

Results for this outcome have not been posted.

Adverse events

Collected over Up to 170 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat276/1,768 (15.6%)973/1,768 (55%)964/1,768 (54.5%)
Darbepoetin Alfa290/1,769 (16.4%)1,032/1,769 (58.3%)993/1,769 (56.1%)
Most frequent serious events
Showing 10 of 1,047
Most frequent serious events
EventVadadustatDarbepoetin Alfa
PneumoniaInfections and infestations140/1768119/1769
Fluid overloadMetabolism and nutrition disorders98/176898/1769
SepsisInfections and infestations76/176888/1769
Acute myocardial infarctionCardiac disorders81/176878/1769
HyperkalaemiaMetabolism and nutrition disorders55/176876/1769
Cardiac arrestCardiac disorders49/176860/1769
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications56/176838/1769
Cardiac failure congestiveCardiac disorders45/176850/1769
Acute respiratory failureRespiratory, thoracic and mediastinal disorders44/176850/1769
Septic shockInfections and infestations44/176845/1769
Most frequent other events
Showing 10 of 17
Most frequent other events
EventVadadustatDarbepoetin Alfa
HypertensionVascular disorders175/1768232/1769
DiarrhoeaGastrointestinal disorders226/1768173/1769
HeadacheNervous system disorders160/1768134/1769
NauseaGastrointestinal disorders148/1768131/1769
FallInjury, poisoning and procedural complications136/1768144/1769
HyperkalaemiaMetabolism and nutrition disorders123/1768137/1769
HypotensionVascular disorders124/1768119/1769
VomitingGastrointestinal disorders119/1768123/1769
Dialysis related complicationInjury, poisoning and procedural complications99/1768122/1769
CoughRespiratory, thoracic and mediastinal disorders99/1768120/1769

Baseline characteristics

Age, Continuous
Age, Continuous(Years)VadadustatDarbepoetin AlfaTotal
Mean57.9 ± 13.8658.4 ± 13.8458.1 ± 13.85
Sex: Female, Male
Sex: Female, Male(Participants)VadadustatDarbepoetin AlfaTotal
Female7877731560
Male99010041994
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VadadustatDarbepoetin AlfaTotal
American Indian or Alaska Native193049
Asian7699175
Black or African American432444876
Native Hawaiian or Other Pacific Islander13619
White113510962231
Not Reported5252104
Reported as Other424587
Multiple8513
Average hemoglobin
Average hemoglobin(Grams per deciliter (g/dL))VadadustatDarbepoetin AlfaTotal
Mean10.249 ± 0.850210.229 ± 0.824510.239 ± 0.8374
Number of Participants on Different Types of Dialysis
Number of Participants on Different Types of Dialysis(Participants)VadadustatDarbepoetin AlfaTotal
Peritoneal Dialysis137143280
Hemodialysis165216333285
Mean Years Since Chronic Dialysis Initiated
Mean Years Since Chronic Dialysis Initiated(Years)VadadustatDarbepoetin AlfaTotal
Mean4.004 ± 4.02243.941 ± 4.01443.973 ± 4.0180
Number of Participants with History of Diabetes
Number of Participants with History of Diabetes(Participants)VadadustatDarbepoetin AlfaTotal
Count of participants7948201614
Number of Participants with NYHA Functional Classification of Heart Failure
Number of Participants with NYHA Functional Classification of Heart Failure(Participants)VadadustatDarbepoetin AlfaTotal
NYHA Class 0124312212464
NYHA Class I268307575
NYHA Class II202192394
NYHA Class III5953112
NYHA Class IV000
NYHA Class Missing549

1 further baseline measures are reported on the registry.

08

Study locations

278 sites
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Mesa, Arizona 85210, United States
  • Research Site
    Pine Bluff, Arkansas 71603, United States
  • Research Site
    Anaheim, California 92801, United States
  • Research Site #1
    Bakersfield, California 93309, United States
  • Research Site #2
    Bakersfield, California 93309, United States
  • Research Site
    Canyon Country, California 91387, United States
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Downey, California 90240, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Fairfield, California 94534, United States
  • Research Site
    Glendale, California 91206, United States
  • Research Site #1
    Granada Hills, California 91344, United States
  • Research Site #2
    Granada Hills, California 91344, United States
  • Research Site
    La Habra, California 90631, United States
  • Research Site
    La Mesa, California 91942, United States
  • Research Site
    Lakewood, California 90712-2512, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Long Beach, California 90813, United States
  • Research Site
    Long Beach, California 92886, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site #1
    Montebello, California 90640, United States
  • Research Site
    Monterey Park, California 91754, United States
  • Research Site
    Newhall, California 91321, United States
  • Research Site #1
    Northridge, California 91324, United States
  • Research Site #2
    Northridge, California 91324, United States
  • Research Site
    Riverside, California 92503, United States
  • Research Site
    Riverside, California 92505, United States
  • Research Site
    Roseville, California 95661, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    San Diego, California 92115, United States
  • Research Site #1
    San Dimas, California 91773, United States
  • Research Site #2
    San Dimas, California 91773, United States
  • Research Site
    Simi Valley, California 93065, United States
  • Research Site
    Tarzana, California 91356, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Whittier, California 90606, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Westminster, Colorado 80031, United States
  • Research Site
    Stamford, Connecticut 06902, United States
  • Research Site
    Bradenton, Florida 34209, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Coral Springs, Florida 33065, United States
  • Research Site
    Coral Springs, Florida 33071, United States
  • Research Site
    Hollywood, Florida 33024, United States
  • Research Site #1
    Lauderdale Lakes, Florida 33313, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Miami, Florida 33125, United States
  • AMPM Research Clinic
    Miami, Florida 33145, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Ocala, Florida 34471, United States
  • Research Site
    Pembroke Pines, Florida 33026, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Augusta, Georgia 30904, United States
  • Research Site #1
    Columbus, Georgia 31904, United States
  • Research Site #2
    Columbus, Georgia 31904, United States
  • Research Site #1
    Lawrenceville, Georgia 30046, United States
  • Research Site #2
    Lawrenceville, Georgia 30046, United States
  • Research Site
    Roswell, Georgia 30076, United States
  • Research Site
    Statesboro, Georgia 30458, United States
  • Research Site
    Meridian, Idaho 83642, United States
  • Research Site
    Fort Wayne, Indiana 46804, United States
  • Research Site
    Merrillville, Indiana 46410, United States
  • Research Site
    Monroe, Louisiana 71201, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Takoma Park, Maryland 20912, United States
  • Research Site
    Springfield, Massachusetts 01107, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Pontiac, Michigan 48341, United States
  • Research Site
    Port Huron, Michigan 91344, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Columbus, Mississippi 39705, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Saint Louis, Missouri 63136, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Gallup, New Mexico 87301, United States
  • Research Site
    Santa Fe, New Mexico 87505, United States
  • Research Site
    Astoria, New York 11102, United States
  • Research Site
    Bronx, New York 10461, United States
  • Research Site
    Flushing, New York 11355, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    New York, New York 10010, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Yonkers, New York 10710, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site #1
    Charlotte, North Carolina 28204, United States
  • Research Site #2
    Charlotte, North Carolina 28204, United States
  • Research Site
    Durham, North Carolina 27704, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site #1
    New Bern, North Carolina 28562, United States
  • Research Site #2
    New Bern, North Carolina 28562, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    Providence, Rhode Island 02903, United States
  • Research Site #1
    Chattanooga, Tennessee 37408, United States

Showing the first 100 of 278 sites across 18 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Eckardt KU, Agarwal R, Aswad A, Awad A, Block GA, Bacci MR, Farag YMK, Fishbane S, Hubert H, Jardine A, Khawaja Z, Koury MJ, Maroni BJ, Matsushita K, McCullough PA, Lewis EF, Luo W, Parfrey PS, Pergola P, Sarnak MJ, Spinowitz B, Tumlin J, Vargo DL, Walters KA, Winkelmayer WC, Wittes J, Zwiech R, Chertow GM. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 Apr 29;384(17):1601-1612. doi: 10.1056/NEJMoa2025956. PubMed 33913638 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jan 2020, 41 months.

Results were first posted in Jun 2022, 2 years 5 months after primary completion. A results delay was requested in Jan 2021.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 41 months is above that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2016
First posted
Sep 8, 2016
StartActual
Aug 2016
Primary completionActual
Jan 16, 2020
CompletionActual
Mar 30, 2020
Results delay requested
Jan 22, 2021
Results first posted
Jun 28, 2022
Last update
Jun 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02892149
Responsible party
Sponsor
First posted
Sep 8, 2016
Start date
Aug 2016
Primary completion
Jan 16, 2020
Completion
Mar 30, 2020
Results posted
Jun 28, 2022
Last update
Jun 28, 2022

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion